The human body produces a natural antibody, a protein called Immunoglobulin E, which is released in much greater amounts when suffering from allergic asthma. It is produced when the body comes in contact with specific allergens, and the excessive amounts of Immunoglobulin E may lead to increased vulnerability to asthma symptoms and make the body prone to attacks.

Immunoglobulin E blockers, also called immunomodulators, are a specific class of drugs for people combating particularly serious long-term cases of allergic asthma which cannot be cured by inhaled steroids or long-acting beta agonists. The use of Immunoglobulin E blockers decreases the need of the patient to consume large doses of steroids, relying on smaller ones instead. The Immunoglobuline E blockers connect themselves to the Immunoglobuline E antibody and prevent it from joining with receptors on mast cells and basophil cells, which are responsible for the inflammation of the respiratory pathways. Thus, by stopping the Immunoglobuline E from bonding with the cells helps to lessen the swelling of the bronchial tubes along with asthmatic symptoms. Also, the patient's reliance on steroids can be lowered by up to 25% in many cases.